Homepage | Spatially targeted eradication of antimicrobial-resistant bacteria

What is the TARGET-THERAPY Project?

Focus

12 March 2026 - 01 January 2030

Appel à projets

Target‑Therapy continues with support from Inserm through the 2025 “Projet de recherche international” (PRI) call

The Target‑Therapy project is progressing into the PHOENIX project, supported by funding from Inserm through the 2025 “Projet de recherche international” (PRI) programme. Read more...

Key data

100%

Project progression

Ended on December 31, 2025

3

Research sites

- Univ Brest (FR)

- Univ Reims (FR)

- Univ Siegen (DE)

15

People

- Researchers

- Postdocs

- PhD students

731 108

Euros

Funded by:

- ANR (FR)

- BMBF (DE)

2nd French-German call for projects on antimicrobial resistance 2020 “One Health: AMR in environmental reservoirs and colonizing antibiotic resistant bacteria”

The specific objective of this project is to significantly improve the treatment of infections with the WHO priority-1 pathogen P. aeruginosa, which is one of the most dangerous key multi-drug resistant bacteria, inside biofilms in the lungs.